Physician profile
Jayrag A Patel
NPI 1528264215
$2,328.81
in general payments reported to CMS, 2019-2025
23 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $110 · 2021: $170 · 2022: $418 · 2023: $731 · 2024: $413 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,631.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $558.25 | 2022-2025 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $408.49 | 2021-2023 | |
| Alcon Vision LLC | $363.34 | 2020-2025 | Clareon, Simbrinza, Tryptyr |
| Sun Pharmaceutical Industries INC. | $107.83 | 2022-2025 | Cequa |
| Kala Pharmaceuticals, INC. | $100.53 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $86.64 | 2024-2025 | Syfovre |
| Harrow Eye, LLC | $82.45 | 2024-2025 | Vevye |
| Dompe US, INC. | $80.10 | 2022-2025 | Oxervate |
| Allergan, INC. | $73.53 | 2021-2022 | |
| Abbvie INC. | $63.07 | 2022-2023 | |
| Ocular Therapeutix, INC. | $61.94 | 2023-2024 | Dextenza |
| Bausch & Lomb Americas INC. | $57.47 | 2022-2025 | Xiidra, Miebo |
| Tarsus Pharmaceuticals, INC. | $42.99 | 2025 | Xdemvy |
| Astellas Pharma US INC | $39.79 | 2025 | Izervay |
| Biotissue Holdings INC. | $35.44 | 2022-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $27.91 | 2020 | |
| Coherus Oncology, INC. | $25.55 | 2023 | |
| Alimera Sciences, INC. | $24.96 | 2023 | Iluvien |
| Horizon Therapeutics Plc | $19.65 | 2023 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $18.12 | 2021 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Ani Pharmaceuticals, INC. | $14.12 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayrag Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.